ATR kinase is a major DNA damage repair protein whose inhibitors have emerged as a promising strategy for cancer treatment and are currently being evaluated in pateints with various solid cancers.[21, 57] However, recent evidence suggests the possibility of non‐DDR functions of ATR in tumor hypoxia, which are critical for the survival of hypoxic cancer cells.[32, 33] Consistent with these reports, we demonstrated that hypoxia sensitised TNBC cells to AZD6738, an ATR inhibitor (Figure 1), through the inhibition of HIF‐1A mediated hypoxia reponses (Figure 2). The gene discussed is HIF1A; the disease is cancer.